The exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market size is expected to see strong growth in the next few years. It will grow to $7.67 billion in 2028 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to telemedicine and remote monitoring, data analytics and ai, patient education and support, regulatory changes and reimbursement policies. Major trends in the forecast period include personalized treatment approaches, development of novel therapies, minimally invasive diagnostics, collaborative care models.
To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/exocrine-pancreatic-insufficiency-epi-therapeutics-and-diagnostics-global-market-report
Segmentation & Regional Insights
The exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market covered in this report is segmented –
1) By Therapies: Nutritional Management; Pancreatic Enzyme Replacement Therapy (PERT); Lifestyle Modifications Approach
2) By Diagnostics: Blood Tests; Magnetic Resonance Imaging (MRI); Endoscopic Ultra-Sonography (EUS); Computerized Tomography (CT) Scanning
3) By Drug Type: Generic; Branded
4) By Distribution Channel: Direct Tender; Retail Pharmacy ; Third-Party Distributor; Other Distribution Channels
5) By End User: Hospitals; Specialty Clinics; Homecare; Diagnostic Center; Research And Academic Institutes; Other End Users
North America was the largest region in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market in 2023. The regions covered in exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12992&type=smp
Major Driver Impacting Market Growth
The increasing number of people with diabetes is expected to propel the growth of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market going forward. Diabetes refers to a chronic metabolic disorder characterized by high blood sugar levels (hyperglycemia) over a prolonged period. This condition results from the body’s inability to produce enough insulin or effectively use the insulin it produces. EPI therapy, which involves pancreatic enzyme replacement therapy (PERT), can help improve nutrient absorption in people with diabetes and EPI. It can also help improve glycemic control in people with diabetes. For instance, in November 2021, according to the International Diabetes Federation, a Belgium-based umbrella organization of over 230 national diabetes associations, approximately 537 million adults (20–79 years old) were living with diabetes in 2021, whereas the total number of people living with diabetes is projected to rise to 643 million by 2030 and 783 million by 2045. Therefore, the increasing number of people with diabetes is driving the growth of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market.
Key Industry Players
Major players in the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market are Pfizer Inc., Merck & Co. Inc., Janssen Pharmaceuticals Inc., AbbVie Inc., Novartis AG, Sanofi S.A., AstraZeneca PLC, Abott Laboratories, Medtronic PLC, Solvay S.A., Laboratory Corporation of America Holdings (Labcorp), Organon group of companies Metagenics LLC, Allergan PLC, Chiesi Farmaceutici S.p.A., Codexis Inc., Nordmark Arzneimittel GmbH & Co. KG, ChiRhoClin Inc., Digestive Care Inc., Alcresta Therapeutics Inc., Vivus Inc., Cilian AG, Bioserv Diagnostics Gmbh, Anthera Pharmaceuticals Inc., Aptalis Pharma Inc., First Wave BioPharma Inc., EagleBiosciences Inc., ScheBo Biotech AG.
The exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market report table of contents includes:
1. Executive Summary
2. Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Characteristics
3. Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Trends And Strategies
4. Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market – Macro Economic Scenario
5. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Size and Growth
………………………..
31. Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Other Major And Innovative Companies
32. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Competitive Benchmarking
33. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market
35. Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Future Outlook and Potential Analysis
Explore the trending research reports from TBRC:
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Market Size - The hazelnut market size has grown strongly in recent years. It will…
Market Size - The IoT gateway devices market size has grown rapidly in recent years.…
The industrial automation cable market size is expected to see strong growth in the next…
Market Size - The zinc rich coating market size has grown rapidly in recent years.…
The fleet management software market size is expected to see rapid growth in the next…
Market Size - The time-sensitive networking (TSN) market size has grown exponentially in recent years.…